Skip to content
Home/Companies/Biotech/Polygon Therapeutics

Polygon Therapeutics

Biotech·France·Active·2yr hold
Entry
2024
Hold
2yr
Status
Active

Who owns Polygon Therapeutics?

Polygon Therapeutics is a French Biotech company, currently owned by Audacia since 2024.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Audacia
Investor
Audacia
Sorbonne Venture by Audacia · 2020 · VC

Key facts

HQFrance
SectorBiotech
StatusActive

More from Sorbonne Venture by Audacia

Other portfolio companies in the same fund.

Biomemory
Active
BiotechFrance· 2025
EVerZom
Active
BiotechFrance· 2025
Austral Dx
Austral Dx
Active
MedTechFrance· 2024

More Audacia portfolio companies

From the same investor, across funds.

Fealinx
Exited 2025
IT ServicesFrance
to DV Group
Geolinks
Active
IndustrialsFrance· 2026
Graforce
Graforce
Active
IndustrialsGermany· 2026
Mantle8
Mantle8
Active
ClimateTechFrance· 2026
Sinergy Flow
Active
ClimateTechItaly· 2026
Chiral Nano
Active
DiversifiedFrance· 2025

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Polygon Therapeutics?

Polygon Therapeutics is currently owned by Audacia, through Sorbonne Venture by Audacia, since 2024.

When did Audacia acquire Polygon Therapeutics?

Audacia acquired Polygon Therapeutics in 2024.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue